Comparative Outcomes of Meropenem and Imipenem in Multidrug-Resistant Pulmonary Infections: A Prospective Cohort...

Area of Science:

• Infectious Diseases
• Pulmonology
• Pharmacology

Background:

• Multidrug-resistant organisms (MDRO) cause severe pulmonary infections with high mortality.
• Carbapenem antibiotics like Meropenem and Imipenem are vital for treating these infections.

Purpose of the Study:

• To compare Meropenem and Imipenem for day-7 pathogen clearance in MDRO pulmonary infections.
• To evaluate secondary clinical and safety outcomes between the two antibiotics.

Main Methods:

• Prospective cohort study design.
• Comparison of Meropenem versus Imipenem in patients with MDRO pulmonary infections.
• Assessment of primary endpoint: day-7 pathogen clearance.
• Evaluation of secondary endpoints: clinical symptom resolution, lung function, inflammatory markers, and adverse events.

Main Results:

• No significant difference in day-7 pathogen clearance between Meropenem and Imipenem (P>0.05).
• Meropenem group showed significantly faster resolution of cough, sputum, lung rales, and fever (P<0.05).
• Meropenem also led to better lung function, reduced PaCO2, lower PCT and hs-CRP, and fewer adverse events (P<0.05).

Conclusions:

• While primary pathogen clearance rates were similar, Meropenem may offer clinical benefits in MDRO pulmonary infections.
• Meropenem demonstrated advantages in symptom resolution, inflammatory markers, and safety profile.
• Findings suggest potential clinical superiority of Meropenem, warranting consideration within the limitations of a non-randomized design.